At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We work together to bring life-changing therapies to patients every day. Start here to find the fulfilling career opportunity that’s right for you. Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" or “@brassring.com” email accounts.
At Biogen, our mission is clear: we are pioneers in neuroscience. Our focus on neuroscience and our deep scientific expertise make us leaders in the research and development of medicines with the potential to transform neuroscience and to benefit society.
That leadership is demonstrated through our commitment to positively impact our communities, to inspire the next generation of scientists, to solve social and environmental challenges and to create a diverse and inclusive workforce that thrives professionally and personally.
Our mission and our impact in the community exemplify our leadership and are vital to the growth of Biogen.
43% of positions at the director level and above are held by women
Four consecutive years ‘Best Place to Work’ for LGBT equality in the U.S.
More than 2,600 employees in 26 countries supported more than 60 volunteer projects as part of the 2017 Care Deeply Day
$6.2 million in community grants and Biogen Foundation employee matching gifts in 2017
5,133 students, along with 524 employee volunteers, participated in our Community Lab programs in 2017 to learn more about science and technology
75% reduction in operational carbon intensity since 2006
Carbon-neutral company since 2014
Engaged with 10 suppliers representing 36% of our supply chain total to reduce GHG emissions in 2017
About the Report
The 2017 Corporate Citizenship Report contains data from calendar year 2017. In some instances, we include information on initiatives or activities that may have begun in 2017, but have continued into 2018.
This report was prepared in accordance with the GRI G4 Guidelines “core” option. Please refer to the GRI Index to see which GRI material aspects and relevant indicators are reported. Also, see below for how we track our efforts in alignment with the U.N. Sustainable Development Goals (SDGs).
For the 2017 report, we are using the 2016 GRI materiality assessment, the most recent GRI materiality assessment available. In this analysis, we identified 18 issues for further attention.
After reviewing the entire list, a set of tier one GRI priorities was agreed upon for immediate attention, including: access to treatments, investments in R&D to ensure a robust pipeline and improved patient outcomes. Throughout this 2017 Corporate Citizenship Report, we explain how Biogen is addressing these issues and measuring performance.
The process to develop the 2016 GRI materiality assessment involved external stakeholder interviews, desk research to establish the broader sustainability context, an internal visioning workshop to prioritize and validate the issues and external stakeholder meetings to review the findings and gather feedback. We intend to conduct a new GRI materiality assessment for the 2018 Corporate Citizenship Report.
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.